BioSpace News Archive

Gvoke® quarterly net sales of $8.1 million Record quarterly Gvoke prescription volume Strong cash position of $136.0 million Conference call and webcast today at 8:30 a.m. ET

IMV Inc., a clinical stage immuno-oncology company announced that IMV’s executive management team will be participating in two upcoming investor conferences

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three months ended March 31, 2021 and provided a business update.

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application for RECORLEV® for the treatment of endogenous Cushing’s syndrome.

Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022.

UroGen Pharma today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Company’s recent developments.

- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collaboration with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters Phase 3 study,

CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.